The week in pharma: action, reaction and insight – week to April 7, 2023
By Barbara Obstoj-Cardwell. Editor
Regulatory news last week featured the combination of Padcev and Keytruda, developed by US biotech Seagen and Japan’s Astellas Pharma, gaining accelerated approval from the US Food and Drug Administration (FDA) for the treatment of urothelial cancer. Also, Germany’s InflaRx gained emergency use authorization (EUA) for its COVID-19 treatment Gohibic (vilobelimab). On the research front, US biotech OncoSec Medical had a major setback last week, when it reported that its TAVO-EP, in combination with Merck & Co’s mega-blockbuster immune-oncology drug Keytruda, missed the endpoint of a Phase II study in melanoma. With better news, UK pharma major AstraZeneca announced positive results from the DUO-O Phase III trial of Lynparza in combination with Imfinzi for the treatment of ovarian cancer.
FDA grants accelerated approval to Padcev + Keytruda in first-line UC
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze